Valuation : Ironwood Pharmaceuticals, Inc.

Market Cap 704M 606M 570M 521M 974M 66.46B 977M 6.73B 2.61B 34.1B 2.64B 2.59B 110B P/E 2026 *
3.48x
P/E 2027 * 3.38x
Enterprise Value 704M 606M 570M 521M 974M 66.46B 977M 6.73B 2.61B 34.1B 2.64B 2.59B 110B EV / Sales 2026 *
1.49x
EV / Sales 2027 * 1.43x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-0.70%
1 week+3.15%
Current month+0.24%
1 month+2.65%
3 months+28.70%
6 months+17.68%
Current year+26.41%
1 week 4.02
Extreme 4.015
4.48
1 month 3.96
Extreme 3.96
4.5
Current year 2.95
Extreme 2.95
5.78
1 year 1.05
Extreme 1.05
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 19/07/2026
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
20/07/26 Free

Chief Technology Officer

137,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-127,890 0.0777%
19/05/26 Free

Chief Financial Officer

25,000 0.0153%
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%+3.15%+268.83%-51.54% 704M
-1.32%+1.33%+77.46%+39.83% 371B
-1.45%-3.14%+24.01%-19.99% 68.64B
-0.51%+4.59%+47.06%+169.41% 12.51B
-1.09%-9.76%-8.26%-9.30% 8.06B
+0.23%-1.59%-20.70%+6.52% 5.04B
0.00%-4.12%-31.60%+22.10% 4.51B
-0.35%-3.11%-33.77%+0.49% 3.07B
-1.00%-0.46%-5.37%+37.06% 2.53B
-0.50%-3.98%-24.35%-17.31% 2B
Average -0.67%-1.50%+29.33%+17.73% 47.79B
Weighted average by Cap. -1.27%+0.87%+64.18%+32.64%

Financials

2026 *2027 *
Net sales 472M 406M 382M 349M 652M 44.53B 654M 4.51B 1.75B 22.85B 1.77B 1.73B 73.6B 494M 425M 400M 365M 683M 46.64B 685M 4.73B 1.83B 23.93B 1.85B 1.81B 77.08B
Net income 203M 175M 165M 150M 281M 19.19B 282M 1.94B 755M 9.85B 763M 747M 31.72B 220M 189M 178M 163M 304M 20.76B 305M 2.1B 816M 10.65B 826M 808M 34.31B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
04/09/26 US$4.260 -0.70% 829,290
03/09/26 US$4.290 -2.72% 1,132,595
02/09/26 US$4.410 +3.28% 2,432,004
01/09/26 US$4.270 +0.47% 1,456,286
31/08/26 US$4.250 +2.91% 1,669,922
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.260USD
Average target price
6.100USD
Spread / Average Target
+43.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock